The Goldman Sachs Group set a €105.00 ($123.53) target price on Sanofi (EPA:SAN) in a research report sent to investors on Monday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.
SAN has been the topic of a number of other reports. Baader Bank restated a buy rating on shares of Sanofi in a research note on Wednesday, June 2nd. Deutsche Bank Aktiengesellschaft set a €75.00 ($88.24) price target on Sanofi and gave the stock a sell rating in a research note on Tuesday, May 11th. Barclays set a €90.00 ($105.88) price objective on Sanofi and gave the company a neutral rating in a research note on Thursday, April 29th. Credit Suisse Group set a €96.00 ($112.94) price objective on Sanofi and gave the company a buy rating in a research note on Wednesday, May 19th. Finally, Jefferies Financial Group set a €110.00 ($129.41) price objective on Sanofi and gave the company a buy rating in a research note on Friday, June 4th. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. Sanofi currently has an average rating of Buy and an average target price of €97.73 ($114.97).
Shares of SAN stock opened at €88.21 ($103.78) on Monday. The stock’s fifty day simple moving average is €86.07. Sanofi has a 1-year low of €63.09 ($74.22) and a 1-year high of €92.97 ($109.38).
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
See Also: Dow Jones Industrial Average (DJIA)
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.